You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 108 No. 1, January 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis

M. B. Abelson, W. A. Chambers and L. M. Smith
Department of Immunology, Eye Research Institute, Boston, Mass.

To evaluate antiallergic agents, we conducted five allergen challenge studies of increasing refinement. The final study design that evolved included two baseline visits, when skin test-positive subjects were administered a bilateral ocular allergen challenge. At the first visit, the threshold dose of reactivity was determined by increasing allergen doses at 10-minute intervals. At the second baseline visit, 3 days later, the responsive subjects were challenged with the final, highest dose used on visit 1 to assure that the allergic reaction was reproducible and not a cumulative effect of multiple allergen doses. The responsive subjects then returned 3 days later for the drug efficacy evaluation. After a slit-lamp examination, subjects were pretreated with the test drug in one eye and the placebo in the fellow eye in a randomized, double-masked fashion. After 10 minutes, subjects were challenged bilaterally with the allergen dose identified on the previous visits. Postchallenge evaluations of hyperemia, itching, chemosis, eyelid swelling, and tearing were performed at 3, 10, and 20 minutes. Subjects were rechallenged 4 hours after drug administration to assess duration of action. Slit-lamp examinations were again performed at the same intervals as after the initial challenge. A total of 396 subjects were given a baseline allergen challenge; 83.6% responded with a moderate (2+) ocular allergic reaction. Of the 266 given a second baseline challenge, 87.2% responded positively again, suggesting that ocular challenge was highly correlated with skin reactivity and reproducible with a second challenge. No statistically significant difference in redness and itching was found when both eyes were challenged with the same dose of allergen.(ABSTRACT TRUNCATED AT 250 WORDS)

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Challenge testing in the diagnosis of occupational allergic conjunctivitis
Wittczak et al.
Occup Med (Lond) 2007;57:532-534.
ABSTRACT | FULL TEXT  

Direct In Vivo Monitoring of Acute Allergic Reactions in Human Conjunctiva
Helinto et al.
J. Immunol. 2004;172:3235-3242.
ABSTRACT | FULL TEXT  

Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus
Mortemousque et al.
Br. J. Ophthalmol. 2004;88:336-340.
ABSTRACT | FULL TEXT  

Efficacy of Ketotifen Fumarate 0.025% Ophthalmic Solution Compared With Placebo in the Conjunctival Allergen Challenge Model
Abelson et al.
Arch Ophthalmol 2003;121:626-630.
ABSTRACT | FULL TEXT  

The Relative Contribution of Mast Cell Subsets to Conjunctival TH2-like Cytokines
Anderson et al.
IOVS 2001;42:995-1001.
ABSTRACT | FULL TEXT  

Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model
Leonardi et al.
Br. J. Ophthalmol. 2000;84:1228-1232.
ABSTRACT | FULL TEXT  

Allergic eye disease mechanisms
McGILL et al.
Br. J. Ophthalmol. 1998;82:1203-1214.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.